← 返回

CAR-T 细胞治疗后病毒和真菌感染的时间线与结局:一项大型数据库分析

英文原题:Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis.

查看英文原题

Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis.

PubMed 2024/11/09(内容时间) Clin Microbiol Infect Q1 · IF 8.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

在一个大型 CAR-T 细胞疗法受者队列中,RVIs 最常见但发生较晚,而疱疹病毒和真菌感染较少见但发生较早。

中文摘要

本大型数据库分析旨在描述嵌合抗原受体(CAR)T细胞治疗后病毒和真菌感染的发生率、时间进程及危险因素。

我们检索全球研究网络数据库TriNetX,筛选接受CAR-T 细胞治疗的患者,并随访其病毒和真菌感染情况。收集基线人口学特征、肿瘤病史、实验室数据和用药史。采用Cox回归分析呼吸道病毒感染(RVI)、疱疹病毒感染、真菌感染及死亡的危险因素。

共纳入2,256例接受CAR-T 细胞治疗的患者,其中1,867例(82.7%)接受靶向CD19治疗,400例(17.7%)接受靶向B细胞成熟抗原治疗。CAR-T 细胞输注后,RVI最常见(23.3%),中位发病时间为160天(四分位距〔IQR〕:52至348天);疱疹病毒和真菌感染较少,发生率分别为13.6%和11.4%,中位发病时间分别为71天(IQR:18至252天)和73天(IQR:14至236天)。多变量Cox回归分析显示,RVI的独立预测因素包括急性淋巴细胞白血病(风险比〔HR〕=1.61)、既往造血细胞移植(HCT;HR=1.29)、细胞因子释放综合征(HR=1.41)、噬血细胞性淋巴组织细胞增多症(HR=1.96)及糖皮质激素(HR=3.37)。既往HCT(HR=2.00)、低丙种球蛋白血症(HR=1.51)、免疫效应细胞相关神经毒性综合征(HR=1.52)和噬血细胞性淋巴组织细胞增多症(HR=1.99)与疱疹病毒感染风险升高相关。真菌感染的独立预测因素包括既往HCT(HR=1.59)、细胞因子释放综合征(HR=1.58)和低丙种球蛋白血症(HR=1.40)。伊德卡布他仑赛与疱疹病毒和真菌感染风险较低相关(HR分别为0.39和0.44)。 讨论:在CAR-T 细胞治疗的大型队列中,RVI最常见但发生较晚;疱疹病毒和真菌感染较少见,但发生较早。该患者群体仍需开展前瞻性研究,评估预防用药和先发监测策略。

展开英文摘要原文

This large database analysis aims to describe the incidence, timeline, and risk factors for viral and fungal infections after chimeric antigen receptor (CAR) T-cell therapy.

We queried a global research network database, TriNetX, for patients who received CAR T-cell therapy, who were identified and followed for the development of viral and fungal infections. Baseline demographic, oncologic history, laboratory data and medication histories were collected. We evaluated risk factors for respiratory viral infections (RVIs), herpesvirus, fungal infections and mortality using Cox regression.

A total of 2256 patients who received CAR T-cell therapy were included, 1867 (82.7%) were CD19-targeted and 400 (17.7%) were B-cell maturation antigen-targeted. After CAR T-cell infusion, RVIs were the most prevalent (23.3%) with a median onset of 160 days (interquartile range [IQR]: 52-348 days), whereas herpesvirus and fungal infections were less frequent, occurring in 13.6% and 11.4% of cases with median onsets of 71 (IQR, 18-252) and 73 days (IQR, 14-236 days), respectively. On multivariable Cox regression, independent predictors of RVI included acute lymphoblastic leukaemia (hazard ratio [HR], 1.61), prior haematopoietic cell transplant (HCT; HR, 1.29), cytokine release syndrome (HR, 1.41), hemophagocytic lymphohistiocytosis (HR, 1.96) and glucocorticoids (HR, 3.37). Prior HCT (HR, 2.00), hypogammaglobulinemia (HR, 1.51), immune effector cell-associated neurotoxicity syndrome (HR, 1.52) and hemophagocytic lymphohistiocytosis (HR, 1.99) were associated with a higher risk of herpesviruses. Independent predictors of fungal infections included prior HCT (HR, 1.59), cytokine release syndrome (HR, 1.58) and hypogammaglobulinemia (HR, 1.40). Idecabtagene vicleucel was associated with a lower risk of herpesvirus and fungal infections (HR, 0.39 and 0.44, respectively). DISCUSSION: In a large cohort of CAR T-cell therapy recipients, RVIs were the most common but occurred later, whereas herpesvirus and fungal infections were less frequent but occurred earlier. Prospective studies investigating prophylaxis and pre-emptive monitoring strategies are needed in this population.

论文信息

作者
Sassine J、Agudelo Higuita NI、Siegrist EA、Saeedi A、Corbisiero MF、Connelly P、Bastias AG、Dib RW
单位
Infectious Diseases Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: joseph-sassine@ouhsc.edu.United States
期刊
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2025 Mar
原文标识
PubMed 39528086 · DOI 10.1016/j.cmi.2024.11.008